Levi & Korsinsky is investigating potential claims on behalf of purchasers of Integra LifeSciences Holdings Corporation (“Integra LifeSciences” or the “Company”) (Nasdaq: IART) securities concerning possible violations of federal securities laws.
For more information, click here:
On January 5, 2012, Integra LifeSciences announced that it received a warning letter from the United States Food and Drug Administration (“FDA”) related to quality systems and compliance issues found at its collagen manufacturing facility located in Plainsboro, New Jersey in August 2011. The Company also announced it expects total revenues in the fourth quarter to be approximately 3% below the low end of previously issued guidance. Upon this news, Integra LifeSciences stock fell 20% on January 6, 2012 to close at $24.49 per share; the stock continues to fall, closing on January 10, 2012 at $23.22 per share.
If you own Integra LifeSciences stock and wish to obtain additional information about the investigation and your legal rights, please contact Joseph E. Levi, Esq. either via email at
or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit
Levi & Korsinsky has expertise in prosecuting investor securities litigation and extensive experience in actions involving financial fraud and represents investors throughout the nation, concentrating its practice in securities and shareholder litigation. Attorney advertising. Prior results do not guarantee similar outcomes.